Abstract:OBJECTIVE:To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).METHODS:Between August 2002 and October 2006, 585 patients underwent allogeneic HSCT (327 related matched donor, 208 mismatched family donor, 44 unrelated volunteer donor, 6 unrelated cord blood) at the Institute of Hematology in Peking University. PTLD was diagnosed on the basis of finding diffuse hyperplasia characterized by invasion of other organ structure with disorganization of the nodal structure in lymph nodes. If pathological investigation was not possible, PTLD was diagnosed by the presence of fever, lymph node enlargement and/or EBV viral load, which could not be explained by other causes. The incidence of PTLD was compared among different groups with chi2 test. Statistics was completed with PC by SPSS 13.0 Microsoft.RESULTS:The incidence of PTLD was 0.3% (1/327) in HLA matched related HSCT patients, 3.4% (7/208) in haploidentical HSCT patients and 2.3% in unrelated HSCT patients. The incidence of PTLD was higher in mismatched or unrelated HSCT group than that in conventional HSCT patients (7/208, 1/44,vs 0/323, P = 0.036). The incidence of PTLD is higher in patients with conditioning regimen including antithymocyte globulin (ATG) than that in patients without (9/262 vs 0/323, P = 0.005) (PTLD occurred in one patient who received reduced-intensity conditioning including ATG, but no PTLD occurred in conventional HSCT). 9 patients developed PTLD. 4 patients were diagnosed with pathology, the remaining 5 with clinical data. Onset of PTLD occurred at a median day of 43 (range 32450). 2 of them it occurred 6 months after HSCT and presented, with local mass and enlarged mediastinum. The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died. In the remaining 7 patients it occurred an early stage after HSCT (day 32-78). 5 of them had a rapidly progressive course characterized by fever and lymphadenopathy, lung or liver or central nervous system involvement and died within weeks. One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor lymphocyte infusion.CONCLUSIONS:Post HSCT PTLD occurs characteristically as disseminated disease with a rapidly progressive and often fulminant course and had a high mortality. It is essential to keep a vigilant eye on it especially in high risk patients.

Successful treatment of post-transplant lymphoproliferative disorder in allogeneic hemopoietic stem cell transplant recipient for severe aplastic anemia

Allogeneic Peripheral Blood Stem Cell Transplantation for Leukemia

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

Etiology, diagnosis, and treatment of post-transplant lymphoproliferative disorders]

[Rituximab based treatment in pediatric Epsstain Bar Virus associated lymphocyte proliferative diseases after aplastic anemia with haplo-identical transplantation:a prospective single centre study]

[Clinical Characteristics, Treatment and Prognosis of PTLD after Allogeneic Hematopoietic Stem Cell Transplantation].

The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation

Clinical Study of Post-Transplantation Lymphoproliferative Diseases in Children with Acquired Aplastic Anemia After Allogeneic Hematopoietic Stem Cell Transplantation

Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review

Poor Outcome in Post Transplant Lymphoproliferative Disorder with Pulmonary Involvement after Allogeneic Hematopoietic SCT: 13 Years' Experience in a Single Institute

[Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia]

A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide

Research Progress on Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation

Risk Factors and Clinical Outcomes of Epstein–Barr Virus DNAemia and Post-Transplant Lymphoproliferative Disorders after Haploidentical and Matched-Sibling PBSCT in Patients with Hematologic Malignancies

Clinicopathologic Spectrum and EBV Status of Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.

Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.

[Early Diagnosis and Comprehensive Treatments of Post-Transplantation Lymphoproliferative Disorder after Pediatric Liver Transplantation].

Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disorder with Significantly Decreased T-cell Chimerism Early after Transplantation: A Case Report

[Post-transplant EBV-associated lymphoproliferative disorders--report of two cases]

[A Clinical Study of Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation].